Skip to main content
John H. Ward

John H. Ward, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Hospital

Clinic 3A, Center for Breast Health
801-213-4269
  • John H. Ward, MD, is the Margaret A. Amundsen Endowed Professor of Medicine. He is a member of the Oncology Division in the Department of Internal Medicine at the University of Utah School of Medicine. Ward is an investigator at the Huntsman Cancer Institute. He served as Chief of the Oncology Division from 1998-2012. He is a past President of the Medical Staff of the University of Utah Hospital and Clinics. He served as the Huntsman Cancer Institute Interim Senior Director of Clinical Affairs and the HCI Interim Physician in Chief from 2019-2021.

    Ward sees patients with a variety of malignant diseases, with an emphasis on breast cancer. Ward represents Huntsman Cancer Institute on the breast cancer treatment guidelines panel of the National Comprehensive Cancer Network. He also provides outreach Hematology/Oncology services for Huntsman Cancer Institute in Jackson Hole, Wyoming.


    A graduate of the University of Utah School of Medicine, Ward completed an internal medicine residency at Duke University where he received the Haskel Schiff award as the outstanding internal medicine resident. He completed a fellowship in hematology/oncology at the University of Utah School of Medicine and has been on the faculty since 1982. Ward is board certified in internal medicine, medical oncology, and hematology. He has received numerous accolades for his teaching excellence, including the 2002 James L. Parkin, MD, award for outstanding clinical teaching at the University of Utah School of Medicine. He received the Huntsman Cancer Foundation Humanitarian Award in 2010. In 2017, he received the Outstanding Clinical Leadership Award of the University of Utah Health Regional Network. In 2021, he was recognized with the Department of Internal Medicine's Chair Award for Lifetime Achievement.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 06, 2022

    Dr. Ward has been my Oncologist since February, 2017. He is an amazing dr and human being! He has always shown me respect for my decisions and concern. I am so grateful that I had him, Rosie and his staff to assist me through the journey!

    July 18, 2022

    Very good

    July 08, 2022

    The doctor takes his time to communicate about my progress and my treatment. And shows genuine care.

    July 08, 2022

    I have loved my experience with Dr. Ward, Rosie, and Allison. It was the best care in such a not so fun situation. I will always think highly of the Hunstmans because of these three special and caring people. Every step of every treatment was explained.

    May 05, 2022

    Dr Ward was very thorough and considerate.

    April 30, 2022

    Excellent unhurried exam and conversation as usual.

    April 15, 2022

    Great

    April 02, 2022

    Good experience

    March 15, 2022

    DrWard is a kind and compassionate Dr. I couldn't see myself with any other Dr on this journey!

  • John H. Ward, MD, is the Margaret A. Amundsen Endowed Professor of Medicine. He is a member of the Oncology Division in the Department of Internal Medicine at the University of Utah School of Medicine. Ward is an investigator at the Huntsman Cancer Institute. He served as Chief of the Oncology Division from 1998-2012. He is a past President of the Medical Staff of the University of Utah Hospital and Clinics. He served as the Huntsman Cancer Institute Interim Senior Director of Clinical Affairs and the HCI Interim Physician in Chief from 2019-2021.

    Ward sees patients with a variety of malignant diseases, with an emphasis on breast cancer. Ward represents Huntsman Cancer Institute on the breast cancer treatment guidelines panel of the National Comprehensive Cancer Network. He also provides outreach Hematology/Oncology services for Huntsman Cancer Institute in Jackson Hole, Wyoming.


    A graduate of the University of Utah School of Medicine, Ward completed an internal medicine residency at Duke University where he received the Haskel Schiff award as the outstanding internal medicine resident. He completed a fellowship in hematology/oncology at the University of Utah School of Medicine and has been on the faculty since 1982. Ward is board certified in internal medicine, medical oncology, and hematology. He has received numerous accolades for his teaching excellence, including the 2002 James L. Parkin, MD, award for outstanding clinical teaching at the University of Utah School of Medicine. He received the Huntsman Cancer Foundation Humanitarian Award in 2010. In 2017, he received the Outstanding Clinical Leadership Award of the University of Utah Health Regional Network. In 2021, he was recognized with the Department of Internal Medicine's Chair Award for Lifetime Achievement.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - University of Utah School of Medicine Fellow
    Internal Medicine - Duke University Medical Center Resident
    Internship Internal Medicine - Duke University Medical Center Intern
    Medicine - University of Utah Hospital School of Medicine M.D.
    Undergraduate University of Utah B.S.

    Selected Publications

    Journal Article

    1. Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), JCO2003609.
    2. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
    3. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R (2021). NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw, 19(5), 484-493.
    4. Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG (2020). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist, 25(11), e1655-e1662.
    5. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(4), 452-478.
    6. Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R (2019). NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw, 17(2), 118-126.
    7. Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N (2003). Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol, 23(2), 132-5.
    8. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996). Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum, 39(2), 325-9.
    9. Mann H, Ward JH, Samlowski WE (1990). Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology, 176(1), 191-4.

    Abstract

    1. Yousef Zakharia, Olivier Rixe, John Harris Ward, Joseph J Drabick, Montaser F Shaheen, Mohammed M Milhem, David Munn, Eugene Paul Kennedy, Nicholas N Vahanian, Charles J Link, Robert R McWilliams, University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA, GRU Cancer Center, Augusta, GA, Huntsman Cancer Inst Univ of Utah, Salt Lake City, UT, Penn State Hershey Medical Center, Hershey, PA, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, Georgia Cancer Center, Augusta University, Augusta, GA, NewLink Genetics Corporation, Ames, IA, Mayo Clinic, Rochester, MN (06/04/2018). Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.Presented at 2018 ASCO Annual meeting June 4, 2018. [Abstract]. J Clin Oncology, 36(suppl. abstr 9512).